Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects on insulin sensitivity and body composition of combination therapy with growth hormone (GH) and insulin-like growth factor-I (IGF-I) in growth hormone deficient adults with impaired glucose tolerance or diabetes.

Next Previous
X
Search
Trial Profile

Effects on insulin sensitivity and body composition of combination therapy with growth hormone (GH) and insulin-like growth factor-I (IGF-I) in growth hormone deficient adults with impaired glucose tolerance or diabetes.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin/mecasermin (Primary)
  • Indications Diabetes mellitus; Glucose intolerance
  • Focus Therapeutic Use
  • Acronyms GH-IGF-I

    • Most Recent Events

    • 24 Mar 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 24 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top